Physician profile
Christopher Jackson
NPI 1093285496
$1,633.77
in general payments reported to CMS, 2019-2025
28 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $313 · 2022: $306 · 2023: $302 · 2024: $301 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $837 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $837.08 |
| Education | $177.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $286.25 | 2022-2025 | |
| Astellas Pharma US INC | $222.13 | 2021-2025 | Xospata |
| Astrazeneca Pharmaceuticals LP | $115.42 | 2021-2024 | Lynparza |
| Amgen INC. | $112.54 | 2021-2025 | Imdelltra (Amg757) |
| Novartis Pharmaceuticals Corporation | $90.51 | 2021-2023 | |
| Pfizer INC. | $88.87 | 2021-2024 | |
| Eisai INC. | $63.39 | 2021-2024 | |
| Seagen INC. | $61.27 | 2021-2023 | Tukysa |
| Pharmacyclics LLC, An Abbvie Company | $60.46 | 2021-2023 | Epkinly |
| Janssen Biotech, INC. | $55.83 | 2021-2023 | Imbruvica |
| Merck Sharp & Dohme LLC | $53.11 | 2021-2022 | |
| Beigene USA, INC. | $44.13 | 2022-2024 | Brukinsa |
| Gilead Sciences, INC. | $42.92 | 2022-2023 | Trodelvy |
| Celgene Corporation | $41.11 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $40.10 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $29.13 | 2021-2023 | Opdivo |
| Aveo Pharmaceuticals, INC. | $26.22 | 2024 | |
| Global Blood Therapeutics, INC. | $24.77 | 2021-2022 | |
| Pharmaessentia USA Corporation | $23.40 | 2023 | Besremi |
| Springworks Therapeutics, INC. | $22.32 | 2025 | Ogsiveo |
| Myovant Sciences INC. | $20.65 | 2022 | |
| Morphosys, US INC. | $18.48 | 2022 | |
| Epizyme, INC. | $16.04 | 2021 | |
| Lilly USA, LLC | $15.29 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.26 | 2023 | Alunbrig |
| Incyte Corporation | $15.26 | 2023 | Jakafi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.51 | 2021 | |
| Tempus Ai, INC | $14.40 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.